Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -11.15% is 62% above its 5-year average of -29.23%, near the high end of its 5-year range (-62.64%–-1.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 34.08% above its 12-month average of -16.91%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -11.15%.
RETURN ON INVESTED CAPITAL (ROIC)
-11.15%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-16.91%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-35.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-29.23%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+34.08%
CURRENT VS 3Y AVG
+68.48%
CURRENT VS 5Y AVG
+61.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
+68.73%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Return on Invested Capital (ROIC)
-11.15%
TTM Avg
-16.91%
3Y Avg
-35.37%
5Y Avg
-29.23%
Market Cap
$3.12B
Return on Invested Capital (ROIC)
-66.60%
TTM Avg
-119.97%
3Y Avg
-72.56%
5Y Avg
-159.91%
Market Cap
$3.30B
Return on Invested Capital (ROIC)
-0.93%
TTM Avg
1.17%
3Y Avg
-16.63%
5Y Avg
-13.35%
Market Cap
$3.31B
Return on Invested Capital (ROIC)
-135.85%
TTM Avg
-39.34%
3Y Avg
-38.88%
5Y Avg
-33.43%
Market Cap
$3.06B
Return on Invested Capital (ROIC)
-50.82%
TTM Avg
-45.69%
3Y Avg
-35.19%
5Y Avg
-27.59%
Market Cap
$3.03B
Return on Invested Capital (ROIC)
-13.88%
TTM Avg
-29.89%
3Y Avg
-36.62%
5Y Avg
-30.08%
Market Cap
$3.36B
Return on Invested Capital (ROIC)
-409.85%
TTM Avg
-257.76%
3Y Avg
-257.76%
5Y Avg
-257.76%
Market Cap
$3.38B
Return on Invested Capital (ROIC)
6.25%
TTM Avg
16.80%
3Y Avg
-7.33%
5Y Avg
-16.60%
Market Cap
$2.99B
Return on Invested Capital (ROIC)
9.95%
TTM Avg
-25.98%
3Y Avg
-51.77%
5Y Avg
-51.95%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | -11.15% | -16.91% | -35.37% | -29.23% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -66.60% | -119.97% | -72.56% | -159.91% |
| CareDx, Inc (CDNA)vs › | $3.30B | -0.93% | 1.17% | -16.63% | -13.35% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | -135.85% | -39.34% | -38.88% | -33.43% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -50.82% | -45.69% | -35.19% | -27.59% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | -13.88% | -29.89% | -36.62% | -30.08% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | -409.85% | -257.76% | -257.76% | -257.76% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 6.25% | 16.80% | -7.33% | -16.60% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 9.95% | -25.98% | -51.77% | -51.95% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -79.40% | -65.84% | -73.62% | -96.54% |
ROIC
-11.1%
ROE
-13.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -11.15% |
| 2026-03-31 | -11.61% |
| 2025-12-31 | -16.64% |
| 2025-09-30 | -20.93% |
| 2025-06-30 | -24.22% |
| 2025-03-31 | -26.34% |
| 2024-12-31 | -40.68% |
| 2024-09-30 | -45.29% |
| 2024-06-30 | -48.07% |
| 2024-03-31 | -50.82% |
| 2023-12-31 | -62.64% |
| 2023-09-30 | -46.42% |
| 2023-06-30 | -54.97% |
| 2023-03-31 | -34.42% |
| 2022-12-31 | -29.52% |
| 2022-09-30 | -27.95% |
| 2022-06-30 | -22.77% |
| 2022-03-31 | -25.10% |
| 2021-12-31 | -7.26% |
| 2021-09-30 | -5.10% |
| 2021-06-30 | -1.88% |
| 2021-03-31 | -7.71% |
| 2020-12-31 | -16.21% |
| 2020-09-30 | -19.30% |
| 2020-06-30 | -13.35% |
